Kornimate/medical-research-clean huggingface dataset:
effects of transcranial magnetic stimulation in incomplete spinal cord injury

Conditions: Spinal Cord Injury

Summary: the main objective is to conduct a study protocol to investigate the effects of repetitive transcranial magnetic stimulation (rtms) on sensory and motor performance of individuals with incomplete spinal cord injury (isci) . a double-blind randomized sham-controlled trial of patients with isci will be conducted.

effective rehabilitation programs for individuals with incomplete spinal cord injury (isci) are required either in the acute or in the post-acute care. rehabilitation techniques based on protocols that selectively stimulate specific pathways along the central nervous system have been considered effective in enhancing neurologic recovery thereby improving functional abilities. the rationale relies on the assumption that the stimulation of the corticospinal tract, primary motor cortex, and spinal cord might induce neuronal reorganization of structures that are largely involved in the control of voluntary movements. in this line of reasoning, protocols involving repetitive transcranial magnetic stimulation (rtms) have been found effective in enhancing corticospinal synaptic transmission, attenuating neuropathic pain, improving spasticity and sensorimotor function after isci. however, controversial findings have also been reported, as other studies showed unaltered central pain, as well as cortical excitability and sensorimotor function. the lack of consistent results is probably associated with differences in stimulation parameters, number of sessions, site of stimulation, chronicity and levels of injury, and outcome measurements of the previous studies. thus, it is clear that there are remaining gaps in our knowledge and the development of new studies, preferably prospective fully double-blind placebo-controlled trials, is necessary to complement the current knowledge about the effects of rtms in patients with isci.

Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of isci with nonprogressive etiology * clinical stability * aged between 18-60 years old * score equal to 24 in the mini-mental state examination * no electroencephalography alterations * absence of depression assessed by hamilton depression scale * currently receiving inpatient rehabilitation in physiotherapy health center of university of the state of paraiba, brazil. exclusion criteria: * have metal prosthesis in some part of the body * use cardiac pacemaker * present dementia or neurological disorders which can increase cortical excitability * have psychotic or schizophrenic disorders * take drugs that reduce seizure threshold or spasticity.

Keywords: incomplete spinal cord injury rehabilitation non-invasive brain stimulation transcranial magnetic stimulation
a study of oseltamivir (tamiflu) for the seasonal prophylaxis of influenza in immunocompromised participants

Conditions: Influenza

Summary: this 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients). transplant recipients enrolled when influenza is circulating in the community will be randomized to receive oseltamivir syrup or capsules 30 milligrams (mg) to 75 mg daily (depending on body weight) or placebo for 12 weeks. influenza symptoms and safety data will be recorded throughout the study.


Eligibility criteria:
inclusion criteria: * negative rapid diagnostic test for influenza at baseline; * immunocompromised participant (liver and/or kidney recipient or allogenic hematopoietic stem cell transplant). exclusion criteria: * symptoms suggestive of influenza-like illness; but not limited to fever, cough, or nasal congestion; * influenza vaccination in 6 weeks prior to randomization; * positive rapid diagnostic test for influenza; * solid organ transplant within 6 months of randomization; * antiviral treatment for influenza in 2 weeks prior to randomization.
co-inhibitory molecules on treg and mir-155-5p in patients with sepsis

Conditions: 28 Day Mortality

Summary: there is high mortality rate of sepsis, 36% in 90-days of sepsis in china, and there is no effective treatment. immunosuppression mediated by sepsis is an important cause of death in patients. treg cells are important immunomodulatory cell. treg's over-differentiation is involved in the development of sepsis induced immunosuppression. in sepsis patients, the expression of pd-1、ctla-4 and tigit on treg cell surface increased, and treg cells with high expression of co-inhibitory molecules showed stronger immunosuppressive characteristics. mir-155-5p is an unencoded rna transcript from a proto-oncogene b cell integration cluster. in sepsis, the expression of mir-155 increased in peripheral blood and correlated with the patient's prognosis. recent studies have shown that mir-155-5p promotes co-inhibitory molecules expressed on t cells in lcmv infected animal models. however, the relationship between the expression of peripheral blood mir-155-5p in sepsis patients and the expression of co-inhibitory molecules on treg cell surface is not clear.

1. peripheral blood treg cells and their surface pd-1、ctla-4 and tigit levels in sepsis patients were measured by flowcytometry. sofa score、apache ii score were recorded 2. the level of mir-155-5p were measured by rt-qpcr in patients with sepsis on day 0-1 and day 3-5, and the correlation between the expression of the co-inhibitory molecules and mir-155-5p were evaluated

Eligibility criteria:
inclusion criteria: * sepsis 3.0 diagnositic criteria are met. older than 18 years old. total course is less than 7 days. informed consent is obatained. exclusion criteria: * pregnancy. patients with active malignant tumors. chronic hepatitis or hiv. patients under treatment with immunosuppressive drugs (except patients with glucocorticosteroid prednisone or equivalent dose\<10 mg/d per day)

Keywords: sepsis immunosuppression treg
inhalation of sevoflurane versus intravenous midazolam,ketamine,propofol for pediatrics undergoing upper gi endoscopy

Conditions: Upper GI Bleeding

Summary: in the field of pediatric gastroenterology, upper gastrointestinal endoscopy has established itself as a diagnostic and therapeutic tool. in order to increase patient tolerance during this procedure, deep sedation is essential. children are at a higher risk of serious adverse effects from procedural sedation; thus, their safety is a primary issue throughout this procedure. multiple studies have been done to find the ideal method for procedural sedation in terms of ease of administration, quality, safety of sedation and recovery profile, but the consensus seems lacking. in this study we will compare between nasal inhalation of sevoflurane versus intravenous ketamine, midazolam and propofol for pediatrics undergoing upper gastrointestinal endoscopy.


Eligibility criteria:
inclusion criteria: 1. a consent from the parents or 1st degree relative. 2. both sexes. 3. pediatric patients aged 1year to 4 years old undergoing 4. elective upper gi endoscopy. 5. asa class i \&ii. 6. bmi between 5th percentile and the 85th percentile (http://www.kidshealth.org). exclusion criteria: 1. hypersensitivity to drugs included in the study. 2. difficult airway or known airway problems. 3. active bleeding from esophageal varices. 4. respiratory and cardiac problems. 5. neurological disorders
perioperative nutrition in gastric bypass surgery

Conditions: Postoperative Complications; Gastric Bypass

Summary: the aim of this study is to demonstrate the influence of peri-operative nutrition on the preservation of lean body mass after gastric bypass, as well as it's influence on postoperative complications.

outcome measures: * lean body mass * length of hospital stay * weight loss * postoperative complications * cost

Eligibility criteria:
inclusion criteria: * rygbp surgery planned * age over 18 * informed consent exclusion criteria: * previous bariatric surgery

Keywords: rygbp early nutrition lean body mass length of stay body composition
ragweed observational study

Conditions: Ragweed Allergy

Summary: this is an observational to evaluate total rhinoconjunctivitis symptom score and rescue medication usage (as measured by rescue medication score as a combined score to inform the design of a phase iii field study with toleromune ragweed.


Eligibility criteria:
inclusion criteria * male or female, aged 18-65 years. * reliable history of rhinoconjunctivitis and/or rhinoconjunctivitis plus controlled asthma on exposure to ragweed allergen for at least 2 years and required symptomatic treatment for at least 1 year. * positive skin prick test (spt) to ambrosia artemisiifolia * specific immunoglobulin e (ige) against ambrosia artemisiifolia \>0.35 ku/l exclusion criteria * positive skin test to any confounding, co-existing seasonal allergens likely to be present during the pre-season baseline and ragweed pollen periods (grasses, miscellaneous weeds, fall trees) and who have received medication for these confounding seasonal allergies. * medical records of symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the subject is regularly exposed (moulds, dust mites, cockroaches, and animal dander) and have received medication for these perennial allergies * subjects with a history of severe drug allergy, severe angioedema or anaphylactic reaction to food or previous spt for any allergen. * subjects with a history of any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, immunopathological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may influence the subject's ability to participate in this study.

Keywords: ragweed allergy
early closure of temporary ileostomy

Conditions: Rectal Cancer

Summary: the study is being conducted as a prospective randomized controlled multicenter study of patients with a temporary ileostomy due to rectal cancer. the study will be conducted in hospitals in denmark and sweden under the framework of the scandinavian surgical outcomes group (www.ssorg.net). the study investigates the effect of reversing a temporary ileostomy after 8-13 days instead of later reversal more than 12 weeks after surgery.

after creation of the temporary ileostomy patients are included and are randomized to two groups. patients in the intervention group will have the stoma closed 8-13 days after stoma creation and will be compared to patients in the control group where the stoma is closed after a minimum of 12 weeks (standard treatment in denmark and sweden). before randomization the eligible patients undergo a ct of the rectum to visualise the anastomosis and possible leakage. furthermore, the local investigators may choose to supplement the ct with a rectoscopy. the research group includes 89 patients over an expected period of 4 years. both groups are examined for postoperative complications as well as stoma-related complications at discharge and 3, 6 and 12 months after stoma creation. the research group also examines the impact on patients´ health-related quality of life at 3, 6 and 12 months after stoma creation. finally the socio-economic effect in both groups will be analyzed and compared 6 and 12 months after stoma creation. an interim analysis is planned for safety as well as recalculation of statistical power.

Eligibility criteria:
inclusion criteria: * patients with a temporary ileostomy after low anterior resection because of rectal cancer * patients, who are physically and mentally fit to undergo surgery within 8-13 days exclusion criteria: * patients whose stoma is not reversible * patients with diabetes * patients being treated with steroids * patients with communicative problems * patients with expected compliance issues

Keywords: rectal cancer temporary ileostomy ealy reversal morbidity mortality quality of life economic effect
efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine

Conditions: Chronic Migraine

Summary: this study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. this study included a 12-week treatment period.


Eligibility criteria:
inclusion criteria: * at least a 1-year history of chronic migraine (cm) consistent with a diagnosis according to the international classification of headache disorders, 3rd edition (ichd-3), 2018 * age of the participant at the time of migraine onset \< 50 years * confirmation of headache/migraine headache day frequency as follows: * history of, on average, ≥ 15 headache days per month in the 3 months prior to visit 1 in the opinion of the investigator and * \>=15 headache days during the 4-week screening/baseline period per the electronic diary (ediary) and * \>=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the ediary * participants must be using a medically acceptable and effective method of birth control during the course of the entire study exclusion criteria: * has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine * has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy * history of an inadequate response to \> 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine * woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. women of childbearing potential must have a negative urine pregnancy test at visit 1 and visit 2.
evaluate safety/efficacy of two treatment regimens for vectical™ ointment & clobex® spray for moderate plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this clinical trial will evaluate the efficacy and safety of clobex® (clobetasol propionate) spray 0.05% and vectical™ (calcitriol) ointment 3 µg/g over a four week period of use in one of two different regimens: 1. vectical™ ointment treatment, twice daily on weekdays (mon - fri) and clobex® spray treatment twice daily on weekends (sat - sun) for 28 days 2. clobex® spray once each morning and vectical™ ointment once each evening for 28 days


Eligibility criteria:
inclusion criteria: * male or female subjects aged 18 to 80 years inclusive * subjects with an overall disease severity of 3 (moderate) * subjects with 3% - 10% treatable bsa (body surface area) excluding scalp, face, groin, axillae and/or other intertriginous areas * for concurrent medications, type and dose must have been stable for at least 3 months prior to study entry and not expected to change during the study. subjects receiving treatment with beta-blockers or lithium, whose dose has been stable for at lest 6 months and who have shown no worsening of their psoriasis, may be included in the study, at the discretion of the investigator exclusion criteria: * subjects with intakes of more than 2,000 iu/day (50 mcg/day) of vitamin d (tolerable upper intake level) and/or more than 1,000 mg/day of calcium * subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas * subjects with a wash-out period for topical treatment less than 30 days (any steroid containing medication, dovonex, anthralin, tar and/or uvb treatment) * subjects with a wash-out period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or puva treatment; examples of these therapies include, but are not limited to puva, soriatane, cyclosporine, hydroxyurea, mycophenolate mofetil, sulfasalazine, azathioprine, alefacept, efalizumab, adalimumab, etanercept, infliximab, rituximab, and methotrexate) * subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis * subjects who foresee intensive uv exposure during the study (mountain sports, uv radiation, sunbathing, etc.)
physical activity and cardiovascular risk in black girls

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Obesity

Summary: to conduct a longitudinal study investigating the physical activity patterns, the psychosocial predictors of physical activity, and the effects of physical activity changes on blood pressure and body fatness in a cohort of african-american girls, ages 11-17.

background: the study contributed to an underdeveloped area of research. physical activity is recommended as a nonpharmacological means to modify hypertension and obesity, two cardiovascular risk factors. african-american women have low levels of physical activity and high rates of obesity, hypertension, and mortality from coronary heart disease, diabetes, and hypertensive diseases. in 1992, there was an absence of longitudinal data about the physical activity habits of african-american girls even though a decline in physical activity during adolescence had been reported in other subpopulations. design narrative: within the framework of puberty and maturation, the study: 1) described longitudinal patterns of physical activity; 2) assessed longitudinal changes in physical activity and concomitant changes in blood pressure and body fatness; and 3) determined psychosocial predictors of changes in physical activity. the investigators hypothesized that there would be a monotonic decrease in physical activity and that psychosocial variables would predict changes in physical activity. the study population consisted of 189 sixth grade, mostly african-american, girls in fort bend independent school district, missouri city, texas. the girls were measured for four and a half years, ages 11 or 12 at entry of the study. anthropometry, sexual maturation, blood pressure, physical activity habits and psychosocial predictors were measured twice a year for a total of nine examinations. data on dietary, smoking and drinking habits were collected annually. activity patterns, psychosocial predictors and other habits were assessed by interviews and questionnaires. sexual maturation was assessed by menarche and the tanner stages. skinfold and circumference measures determined body fatness and body fat distribution.

Eligibility criteria:
no eligibility criteria
the cognaive study: assessing changes in neurocognitive function in treatment naïve hiv-1 positive subjects

Conditions: HIV Infections

Summary: the purpose of this study is to investigate the possibility of an association between changes in neurocognitive function, as measured by a computerised test battery, and the use of two different highly active antiretroviral therapy (haart) regimens in treatment naïve hiv-1 infected subjects commencing antiretroviral therapy.


Eligibility criteria:
inclusion criteria: * hiv-1 infected males or females * signed informed consent * no previous antiretroviral treatment * males with cd4+ lymphocyte count \< 400 cells/ųl and females with cd4+ lymphocyte count \< 250 cells/ųl * susceptible to all currently licensed nucleoside reverse transcriptase inhibitors (nrtis), non-nucleoside reverse transcriptase inhibitors (nnrtis) and protease inhibitors (pis) exclusion criteria: * existing neurological disease * hepatitis b or hepatitis c co-infection * current history of major depression or psychosis * recent head injury * current alcohol abuse or drug dependence * active opportunistic infection or significant co-morbidities

Keywords: antiretroviral therapy neurocognitive function magnetic resonance spectroscopy hiv disease treatment naive
bipolar h.a versus trochanteric antegrade nail for treatment of displaced subcapital femoral fractures

Conditions: Displaced Subcapital Femoral Fracture

Summary: a retrospective study to compare clinical results of patients that were treated by bipolar h.a. vs. closed reduction and internal fixation with trochanteric antegrade nail for displaced femoral subcapital fracture.


Eligibility criteria:
inclusion criteria: * displaced femoral subcapital fracture. * active patient. * age 40-85. * patient was treated by one of the two methods. exclusion criteria: * age out of range.

Keywords: displaced subcapital femoral fracture bbipolar h.a. crif with ttrochanteric antegrade nail
calf muscle strength in mitochondrial diseases

Conditions: Mitochondrial Disease

Summary: mitochondrial disorders are a group of inherited disorders causing malfunctional mitochondria. mitochondria are found in every cell of the body, and the disorders therefore give symptoms from every tissue, especially those with high energy needs as the brain, heart and muscles. the disorders are highly disabling. the aim of the study is to investigate the relation between muscle strength and contractile cross sectional area (ccsa) in the leg of patients affected by mitochondrial diseases. the hypothesis is that there can be a disrupted relationship between strength and ccsa.

mitochondrial disorders are a group of inherited disorders caused by mutations in genes encoding mitochondrial proteins. the proteins are encoded by genes from both the mitochondrial dna (mtdna) and the nucleus, making some of the disorders maternally inherited and some autosomal recessive or dominant. the mitochondria are found in almost all cells in the body and are the main source of energy. the energy is produced through the electron transport chain, which is composed of four multi subunit complexes (i to iv). a mutation in one or more of these complexes is a typical cause of a mitochondrial disease. since the mitochondria are found in almost every cell, mitochondrial disease can give rise to symptoms from many organs. the symptoms depend on what kind of mutation the patient has, but usually includes muscular and neurological problems, as these cells have especially high energy needs. it is believed that the muscle weakness in mitochondrial diseases is caused by the reduced ability to produce energy. however, recent research has suggested that there is a structural change in the muscles as well. the hypothesis is that this structural change in the muscles will affect its function. the aim of the study is to investigate the relation between muscle strength and contractile cross sectional area (ccsa) in the calf of patients affected by mitochondrial diseases. in healthy individuals there is a close relation between strength and ccsa, as the strength will decrease according to a decrease in ccsa. in mitochondrial disease, the hypothesis is that there can be a disrupted relationship between strength and ccsa. the investigators will recruit 30 subjects with verified mitochondrial disease, and compare the results to that of healthy individuals (results from an earlier research project). a dixon mri will be used to find the ccsa of the calf muscle and a muscle dynamometer will be used to find the strength. these two variables are compared.

Eligibility criteria:
inclusion criteria: * verified mitochondrial disease. * age: over 18 years old exclusion criteria: * contraindications for an mri. * claustrophobia. * pregnant or nursing women. * competing disorders (as arthritis) or other muscle disorders.

Keywords: mri ccsa contractile cross sectional area strength calf muscle